IL224120A - A compound for the production of inhibitors for meteloproteins - Google Patents

A compound for the production of inhibitors for meteloproteins

Info

Publication number
IL224120A
IL224120A IL224120A IL22412013A IL224120A IL 224120 A IL224120 A IL 224120A IL 224120 A IL224120 A IL 224120A IL 22412013 A IL22412013 A IL 22412013A IL 224120 A IL224120 A IL 224120A
Authority
IL
Israel
Prior art keywords
mmp
antibodies
antibody
ser
pro
Prior art date
Application number
IL224120A
Other languages
English (en)
Hebrew (he)
Inventor
Shanzer Abraham
Sagi Irit
Danon Tamar
Sela Netta
Kikkeri Raghavendra
Arad-Yellin Rina
Original Assignee
Yeda Res & Dev
Shanzer Abraham
Sagi Irit
Danon Tamar
Sela Netta
Kikkeri Raghavendra
Arad-Yellin Rina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Shanzer Abraham, Sagi Irit, Danon Tamar, Sela Netta, Kikkeri Raghavendra, Arad-Yellin Rina filed Critical Yeda Res & Dev
Publication of IL224120A publication Critical patent/IL224120A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/06—Zinc compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL224120A 2007-02-23 2013-01-06 A compound for the production of inhibitors for meteloproteins IL224120A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90285407P 2007-02-23 2007-02-23
PCT/IL2008/000230 WO2008102359A1 (en) 2007-02-23 2008-02-21 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

Publications (1)

Publication Number Publication Date
IL224120A true IL224120A (en) 2016-05-31

Family

ID=39534848

Family Applications (2)

Application Number Title Priority Date Filing Date
IL224120A IL224120A (en) 2007-02-23 2013-01-06 A compound for the production of inhibitors for meteloproteins
IL224121A IL224121A (en) 2007-02-23 2013-01-06 Use of Matrix-9 and 2 Matrix Protease Inhibitors for the Treatment of Disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL224121A IL224121A (en) 2007-02-23 2013-01-06 Use of Matrix-9 and 2 Matrix Protease Inhibitors for the Treatment of Disease

Country Status (11)

Country Link
US (5) US8324355B2 (enExample)
EP (1) EP2155691B1 (enExample)
JP (2) JP5513130B2 (enExample)
KR (1) KR20090113908A (enExample)
CN (1) CN101702906B (enExample)
BR (1) BRPI0807256A2 (enExample)
CA (1) CA2678304A1 (enExample)
IL (2) IL224120A (enExample)
MX (1) MX2009008914A (enExample)
RU (1) RU2503682C2 (enExample)
WO (1) WO2008102359A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101702906B (zh) 2007-02-23 2014-02-12 耶达研究及发展有限公司 用于抑制金属蛋白活性的抗体和含有所述抗体的药物组合物
EP2231186A4 (en) 2007-12-17 2012-08-08 Dyax Corp COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
AU2009221916A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
EP2403964B1 (en) * 2009-03-02 2021-09-08 Massachusetts Institute of Technology Methods and products for in vivo enzyme profiling
WO2011092700A1 (en) 2010-01-27 2011-08-04 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
SI2608809T1 (sl) 2010-08-27 2019-08-30 Gilead Biologics, Inc. Protitelesa proti matriksu metaloproteinaze 9
ES2688457T3 (es) 2010-10-28 2018-11-02 Yeda Research And Development Co. Ltd. Métodos de generación de anticuerpos contra metaloenzimas
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
BR112014021081A2 (pt) 2012-02-29 2017-07-04 Gilead Biologics Inc anticorpos para a metaloproteinase da matriz 9
WO2014197840A1 (en) 2013-06-07 2014-12-11 Massachusetts Institute Of Technology Affinity-based detection of ligand-encoded synthetic biomarkers
RU2729546C2 (ru) 2014-04-03 2020-08-07 Цсл Беринг Аг Распыление иммуноглобулина
US11019620B2 (en) 2014-05-19 2021-05-25 Qualcomm Incorporated Apparatus and method for inter-band pairing of carriers for time division duplex transmit- and receive-switching and its application to multiplexing of different transmission time intervals
US11452121B2 (en) * 2014-05-19 2022-09-20 Qualcomm Incorporated Apparatus and method for synchronous multiplexing and multiple access for different latency targets utilizing thin control
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
US10305637B2 (en) * 2016-04-04 2019-05-28 Samsung Electronics Co., Ltd. Method and apparatus for transmitting and receiving feedback in wireless communication system
EP3634459A4 (en) * 2017-02-10 2021-01-06 Washington University ANTIBODIES DIRECTED AGAINST TIP1 AND THEIR PROCEDURES FOR USE
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
US11926655B2 (en) 2017-07-18 2024-03-12 Daiichi Sankyo Company, Limited Active MMP9-binding peptide
WO2020068920A2 (en) 2018-09-25 2020-04-02 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
WO2020150560A1 (en) 2019-01-17 2020-07-23 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
CA3212755A1 (en) * 2021-04-05 2022-10-13 Thomas J. Montine Enantiomer selective action on neurotransmission
WO2025075789A1 (en) * 2023-10-03 2025-04-10 Merck Sharp & Dohme Llc Immunoassay for detecting tau phosphorylated at serine 413
AU2024356800A1 (en) 2023-10-05 2026-04-02 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
WO2026076260A1 (en) 2024-10-03 2026-04-09 Ashibio, Inc. Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
JP3348725B2 (ja) 1992-04-07 2002-11-20 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
AU2361295A (en) 1994-04-28 1995-11-29 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
EP0757984B1 (en) 1995-08-08 2002-10-30 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives useful for inhibiting gelatinase
IL116126A0 (en) * 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
WO1997024117A1 (en) 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
WO1997049679A1 (en) 1996-06-27 1997-12-31 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
NZ509439A (en) 1998-07-30 2002-10-25 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
IL132105A0 (en) * 1998-12-24 2001-03-19 Yeda Res & Dev Caspase-8 interacting proteins
ES2369498T3 (es) * 2003-04-04 2011-12-01 Yeda Research And Development Co., Ltd. Anticuerpos para inhibir la actividad de mmp-2 y mmp-9.
CN101702906B (zh) 2007-02-23 2014-02-12 耶达研究及发展有限公司 用于抑制金属蛋白活性的抗体和含有所述抗体的药物组合物
WO2011092700A1 (en) 2010-01-27 2011-08-04 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins

Also Published As

Publication number Publication date
US20130224225A1 (en) 2013-08-29
JP5792231B2 (ja) 2015-10-07
US20100233188A1 (en) 2010-09-16
US9902783B2 (en) 2018-02-27
MX2009008914A (es) 2009-08-28
JP2010519289A (ja) 2010-06-03
US20130030158A1 (en) 2013-01-31
KR20090113908A (ko) 2009-11-02
US20160257765A1 (en) 2016-09-08
US8324355B2 (en) 2012-12-04
WO2008102359A9 (en) 2009-05-22
US20180134808A1 (en) 2018-05-17
BRPI0807256A2 (pt) 2014-07-22
CN101702906A (zh) 2010-05-05
US9416195B2 (en) 2016-08-16
CN101702906B (zh) 2014-02-12
CA2678304A1 (en) 2008-08-28
IL224121A (en) 2016-05-31
EP2155691A1 (en) 2010-02-24
RU2009132006A (ru) 2011-02-27
EP2155691B1 (en) 2016-01-13
WO2008102359A1 (en) 2008-08-28
RU2503682C2 (ru) 2014-01-10
JP5513130B2 (ja) 2014-06-04
US8486653B2 (en) 2013-07-16
JP2013241435A (ja) 2013-12-05
AU2008218525A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
IL224121A (en) Use of Matrix-9 and 2 Matrix Protease Inhibitors for the Treatment of Disease
US8841108B2 (en) Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
CN102822202B (zh) 抑制金属蛋白的抗体
AU2008218525B2 (en) Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
EP2632956A1 (en) Methods of generating antibodies to metalloenzymes
HK1142331A (en) Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
IL171156A (en) Antibodies useful for inhibiting activity of metalloenzymes, uses thereof and methods of generating same
CA2052501A1 (en) Monoclonal antibodies directed against complexes formed by thrombin and thrombin inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed